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ABSTRACT Understanding how oncogenic transforma-
tion sensitizes cells to apoptosis may provide a strategy to kill
tumor cells selectively. We previously developed a cell-free
system that recapitulates oncogene dependent apoptosis as
ref lected by activation of caspases, the core of the apoptotic
machinery. Here, we show that this activation requires a
previously identified apoptosis-promoting complex consisting
of caspase-9, APAF-1, and cytochrome c. As predicted by the
in vitro system, preventing caspase-9 activation blocked drug-
induced apoptosis in cells sensitized by E1A, an adenoviral
oncogene. Oncogenes, such as E1A, appear to facilitate
caspase-9 activation by several mechanisms, including the
control of cytochrome c release from the mitochondria.
Expression of oncogenes that deregulate the cell cycle can
either induce apoptosis or sensitize cells to proapoptotic
stimuli (1, 2). An implication of this observation is that
oncogene expression generates a proapoptotic signal that is
present in transformed cells but absent in normal cells. When
this signal is uncoupled from the apoptotic machinery, trans-
formed cells can survive and become resistant to chemother-
apeutic drugs. In principle, restoring the link between the
signal and the apoptotic machinery should selectively kill
transformed cells because, although untransformed cells have
the machinery, they lack the signal. Understanding how the
apoptotic machinery is regulated by oncogenic transformation
is the first step in testing this hypothesis.
A central component of the apoptotic machinery is a family
of cysteine proteases called caspases (3). Caspases are ex-
pressed as inactive precursors that are activated by proteolytic
processing. According to the current model (4), two classes of
caspases, initiators and effectors, are involved in apoptosis.
Proapoptotic signals activate initiator caspases, such as
caspase-2, -8, and -9. This activation is autocatalytic and
requires the binding of specific cofactors. Activated initiator
caspases process effector caspases (caspase-3, -6, and -7),
which in turn cause cell collapse by cleaving a specific set of
substrates. It appears that each initiator caspase is activated in
response to a subset of signals, indicating that a prerequisite for
understanding how a specific signal activates apoptosis is
linking this signal to a particular initiator caspase. The initiator
caspase that mediates oncogene-dependent apoptosis has thus
far been elusive (5, 6).
To investigate how the apoptotic machinery is regulated by
oncogene expression, our laboratory previously developed a
cell-free system that mimics oncogene-dependent apoptosis
(7). This system is based on the observation that extracts from
cells transformed with the adenoviral oncogene E1A (‘‘trans-
formed extracts’’) spontaneously activated caspases whereas
extracts from untransformed cells (‘‘untransformed extracts’’)
did not, an observation consistent with the proapoptotic effect
of this oncogene in cells (8). It was suggested that the activity
that triggered caspase activation is induced by expression of
E1A, and this activity was called oncogene-generated activity
(OGA) (7). OGA partially purified from 293 cells [a trans-
formed human epithelial kidney cell line that expresses the
E1A and E1B oncogenes (9)] activated caspases when added
to untransformed extracts, thus mimicking the effects of E1A
expression in cells. Therefore, we suggested that OGA is a link
between oncogene expression and the apoptotic machinery.
Here we have purified OGA to apparent homogeneity and
have identified it as APAF-1, a cofactor required for caspase-9
activation (10). We found that caspase-9 indeed was required
for caspase activation in our cell free system, as was cyto-
chrome c (Cyt c), a second caspase-9 cofactor (10). These
observations predicted that caspase-9 is the initiator caspase
that mediates oncogene-dependent apoptosis in cells and that
expression of oncogenes sensitizes cells to apoptosis by facil-
itating activation of this caspase. To test these predictions we
used human primary fibroblasts (IMR90) that were sensitized
to drug-induced apoptosis by expression of adenoviral onco-
gene E1A. Consistent with the results from the cell free system,
a caspase-9 dominant negative mutant blocked drug-induced
apoptosis in cells expressing E1A. This finding led us to
investigate how E1A expression controlled caspase-9 activa-
tion. We conclude that this control is achieved through several
mechanisms, one of which is regulating Cyt c release from
mitochondria.
MATERIALS AND METHODS
Extract Preparation. All extracts were prepared as de-
scribed (7).
Purification of OGA. OGA was purified by using a recon-
stitution and a complementation assay. In the reconstitution
assay, an aliquot from each fraction (4 ml) was mixed with the
flow through from Fast Flow Q chromatography (5 ml) and
ATP (1 ml, 1 mM final concentration). In the complementation
assay, an aliquot from each fraction (4 ml) was mixed with
extract from IMR90 cells (5 ml) and ATP. In both assays, the
mixture was incubated at 37°C for 15 min, and then caspase
activity was measured by using a f luorogenic substrate,
DEVD.afc (7), and was expressed as picomoles of free afc
generated per minute per milligram of extract.
Cell extracts (293 extracts; 2 g from 80 liters of cell suspen-
sion) in buffer A (50 mM Pipes, pH 7y10 mM KCly5 mM
EGTAy1 mM MgCl2y1 mM DTTy0.1 mM phenylmethylsul-
fonyl f luoride) were loaded onto a Fast Flow Q column
(250-ml bed vol). The flow through (FT) was concentrated by
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ultrafiltration and was used for the reconstitution assay. The
0.1 M KCl eluate (designated F1) was collected, potassium
phosphate was added to 10 mM, and the solution was loaded
onto a hydroxyapatite column (60-ml bed vol). The activity was
eluted with 0.4 M potassium phosphate, was dialyzed against
100 mM Hepes (pH 7.5), 25 mM KCl, 5 mM EGTA, 1 mM
MgCl2, and 1 mM DTT and was loaded onto POROS HS (8-ml
bed vol). The activity was eluted with 25–500 mM KCl gradient
and was supplemented with ammonium sulfate (30% satura-
tion), and the soluble protein was loaded onto POROS PH
(1.6-ml bed vol.). The activity was eluted with a 0–30%
ammonium sulfate linear gradient, was loaded onto a Superdex
200 column, and eluted in buffer A supplemented with 100
mM KCl. Eluted fractions were dialyzed against buffer A and
were assayed for activity.
Peptide Sequencing and Mass Spectrometry. Protein se-
quencing was performed as described (11). The sequence of
the peptides obtained corresponded exactly to residues 64–81,
82–98, 267–277, 421–437, 640–644, 774–791, 951–963, 1015–
1023, and 1169–1176 of APAF-1. In addition, the masses of an
additional eight peptides were determined by mass spectrom-
etry and are predicted to derive from APAF-1.
mAbs. Antibodies were prepared by using an the N-terminal
fragment (amino acids 1–134) of caspase-9 and the full length
caspases 7 and 8 as antigens. None of the antibodies crossre-
acted with all caspases tested, which were 3, 6, 7, and 8 for the
caspase-9 antibody; 3, 6, 7, and 9 for caspase-8 antibody; and
3, 6, 8, and 9 for caspase 7 antibody. Antibody to APAF-1 was
prepared by using a 50-kDa N-terminal fragment of the
protein.
Immunodepletion of Caspase-9. The antibodies were bound
to protein A Sepharose (Pharmacia) according to the manu-
facturer’s instructions. Ten milligrams of 293 cell extract (300
ml) was incubated with either the bound antibody or just
protein A Sepharose for 3 hours at 4°C. Aliquots were assayed
for caspase activation by the fluorogenic assay and were
analyzed for caspase-9 depletion by immunoblotting.
Recombinant Caspase-9. Caspase-9 precursor with a car-
boxy-terminal histidine tag was expressed by using the pET-21
mch6 expression vector provided by E. Alnemri (Kimmel
Cancer Institute, Philadelphia). The caspase-9 Cys287 to Ser
mutant was prepared by using the Quick Change kit (Strat-
agene). Caspase-9 and the mutant were purified on Ni-NTA-
agarose (Qiagen, Chatsworth, CA) followed by chromatogra-
phy on Resource Q (Pharmacia).
Caspase-9 Gene Transfer. cDNA encoding caspase-9 with a
carboxy-terminal Flag epitope tag and the caspase Cys287 to
Ser mutant were cloned into a MarxIV-puro retroviral gene
transfer vector. Retrovirus was produced by transfection into
LinX-A packaging cells (L. Y. Xie, D. Beach, and G.J.H.,
unpublished material). Medium from transfected LinX cells
supplemented with 8 mgyml Polybrene was diluted 1:2 with
fresh medium and was added to plates of IMR90-E1A cells.
Plates were centrifuged at 1,000 3 g for 1 hour and then were
incubated for 12–18 hours at 32°C. Medium then was replaced
after 2 days, and infected cells were selected by using puro-
mycin (1 mgyml) for 4 days.
Scoring Apoptosis. The cells were harvested by combining
floating cells in the media with adherent cells that were
detached with EDTA (3 mM) and EGTA (3 mM) in PBS. Cells
were fixed in 4% paraformaldehyde and were stained with
49,6-diamidino-2-phenylindole (0.5 mg/mly0.1% Triton in
PBS). The percentage of cells with apoptotic nuclear mor-
phology then was determined.
Immunofluorescence Staining of Cyt c. Cells were grown on
coverslips coated in Pronectin F Plus (Protein Polymer Tech-
nologies, San Diego), were fixed in 4% paraformaldehyde,
were permeabilized in 0.2% Triton, and were blocked with 2%
BSA and 2% goat serum. Cells were incubated with anti-Cyt
c antibody (a gift from R. Jemmerson, University of Minne-
sota) at 1 mgyml followed by a secondary antibody conjugated
to Alexa 594 (Molecular Probes). Cells were stained with
49,6-diamidino-2-phenylindole, and the coverslips were
mounted by using Prolong Antifade (Molecular Probes).
RESULTS AND DISCUSSION
Previously, we partially purified OGA from 293 cell extracts by
using ion-exchange chromatography. This procedure sepa-
rated the extract into three fractions (F1, F2, and FT). None
of these fractions had caspase activity, but combining F1 and
FT reconstituted caspase activation (7). One of the fractions,
FIG. 1. Purification of OGA. (A) OGA was purified as described in Materials and Methods. Shown are the fractions from each step with maximal
activity. Size exclusion chromatography, the last step in purification, provided a single polypeptide of '130 kDa (B) that coeluted with activity
(C and E). This polypeptide reacted with an antibody to APAF-1 (D). Purification was done twice with similar results.
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F1, activated caspases when added to untransformed extracts,
thereby mimicking the effect of E1A expression. We therefore
concluded that F1 contained OGA, and, in this study, we used
this fraction to purify OGA to homogeneity.
OGA is APAF-1. Purification of OGA relied on two assays.
In the ‘‘reconstitution’’ assay, we analyzed fractions obtained
during purification for the ability to reconstitute caspase
activation when recombined with FT. In the ‘‘complementa-
tion’’ assay, these fractions were tested for the ability to
activate caspases in extracts from primary human fibroblasts
(IMR90 cells), which, in contrast to extracts from IMR90 cells
transformed with E1A, do not activate caspases spontaneously
in the presence of ATP (Fig. 1E). Throughout the purification,
fractions that reconstituted activation coincided with those
that activated untransformed extracts.
OGA was purified to homogeneity by using five chromato-
graphic steps (Fig. 1A and Materials and Methods). The last
step in purification gave a single polypeptide of '130 kDa, as
estimated by SDSyPAGE (Fig. 1B), that activated caspases in
the reconstitution (Fig. 1C) and the complementation assays
(Fig. 1E). Both reactions depended on ATP, consistent with
the previous characterization of OGA (7).
The size of the polypeptide and its ability to activate caspases
suggested OGA was APAF-1, a known cofactor for caspase-9
activation (10). Indeed, an antibody to APAF-1 (a gift from X.
Wang, University of Texas Southwestern Medical Center)
reacted with the purified protein (Fig. 1D). To unambiguously
identify the purified protein, we obtained peptide sequence.
Ten OGA peptide fragments exactly matched the APAF-1
sequence (see Materials and Methods). The finding that OGA
is APAF-1 suggested that E1A-dependent apoptosis is medi-
ated by caspase-9. We set out to test this possibility in both the
cell free system and in intact cells.
Caspase-9 Is Required for Oncogene-Dependent Caspase
Activation in Vitro. APAF-1 and Cyt c were identified as
cofactors for dATP-dependent activation of caspase-9 in cell
extracts (10). Adding dATP activates caspases in both trans-
formed and untransformed extracts (7) whereas adding ATP
activates caspases only in transformed extracts. Hence, E1A-
dependent caspase activation is revealed in the presence of
ATP. Therefore, we first tested whether ATP-dependent
caspase activation also requires caspase-9 and Cyt c.
Caspase-9 is processed in transformed extracts earlier than
is caspase-3, the effector caspase responsible for the bulk of the
detected caspase activity (A. Doseff and Y.A.L., unpublished
material). To test whether caspase-9 was required for caspase
activation, it was depleted from extracts (Fig. 2A). Depletion
greatly reduced caspase activation whereas mock depletion
had a much lesser effect (Fig. 2B), consistent with caspase-9
being required for caspase activation in this system.
To test that the effect of depletion was caused by the removal
of caspase-9, we complemented depleted extracts with recom-
binant pro-caspase-9. The recombinant protein reconstituted
caspase activation (Fig. 2B), although the amount required
exceeded endogenous levels by at least 20-fold, perhaps be-
cause of the differences between endogenous and recombinant
proteins. The complementation effect of caspase-9 was ATP-
dependent and required APAF-1, indicating that this effect is
caused by processing of caspase-9 rather than to a contami-
nation with the active enzyme (data not shown).
To test whether Cyt c was required for ATP-dependent
caspase activation, we depleted this protein from FT, the
fraction that complements APAF-1 in the reconstitution assay,
by using phosphocellulose (Fig. 2C). The resulting fraction,
FT-P, failed to reconstitute caspase activation when combined
with APAF-1 (Fig. 2D). Activation was restored by adding
either exogenous Cyt c or by adding the eluate from phospho-
cellulose (Fig. 2D and data not shown). Hence, ATP-
dependent caspase activation in our cell-free system did re-
quire Cyt c and was mediated by caspase-9.
Caspase-9 Mediates Oncogene-Dependent Apoptosis in
Cells. The finding that OGA is APAF-1 and the observation
FIG. 2. Oncogene-dependent caspase activation in the cell-free system requires caspase-9 and Cyt c. (A) Depletion of caspase-9. The 293-extract
(Input) was depleted of caspase-9 by using protein A Sepharose bound to a caspase-9 antibody (a-casp9) or was mock-depleted by omitting the
antibody. Caspase-9 remaining in extracts (S) and bound to the Sepharose (P) was assessed by immunoblotting by using the same antibody. The
two additional bands are IgG. (B) Depletion of caspase-9 abolished caspase activation, which was restored by adding recombinant caspase-9. Data
are typical of three experiments. (C) Depletion of Cyt c. The FT fraction (input), used in the reconstitution assay, was depleted of Cyt c by passing
it over a phosphocellulose column. The resultant flow through (FT-P) had no Cyt c detectable by immunoblotting. (D) Cyt c is required for caspase
activation. FT-P was mixed with ATP (1 mM) and APAF-1 ('1 fmol) with or without Cyt c ('20 pmol) as indicated. Results shown are typical
of two experiments.
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that oncogene-dependent caspase activation in vitro is medi-
ated by caspase-9 predicted that the proapoptotic effect of
E1A in cells is achieved through caspase-9. Therefore, we
tested this prediction by using a dominant negative mutant of
caspase-9 (caspase-9 DN) (12). Caspase-9 DN can bind co-
factors but cannot undergo autocatalytic processing because of
a mutation that substitutes serine for the catalytic Cys287. As
a result, caspase-9 DN can compete for binding to cofactors
with the endogenous enzyme, thereby preventing activation.
Consistent with the requirement for caspase-9 in our cell-free
system, caspase-9 DN inhibited caspase activation when added
to the 293 extract (data not shown).
To test the effect of caspase-9 DN on oncogene-dependent
apoptosis in cells, we used IMR90 fibroblasts transformed with
E1A. In these cells, drug-induced apoptosis is oncogene-
dependent because untransformed IMR90 cells are resistant to
apoptosis induced by chemotherapeutic drugs but IMR90 cells
expressing E1A are sensitive (13). When IMR90-E1A cells
were treated with the chemotherapeutic drug etoposide, the
cells underwent apoptosis as judged by cell morphology and
chromatin condensation (Fig. 3A and Fig. 4A), by detection of
caspases 3 and 7 processing (Fig. 3 B and C), by Annexin V
staining, and by DFF cleavage (data not shown). Expression of
caspase-9 DN abolished all of these changes, consistent with
the notion that oncogene-dependent sensitization is mediated
by caspase-9 (Fig. 3A and data not shown).
Although etoposide treatment caused caspase-9 processing
in cells infected with either vector alone or with caspase-9, this
processing was not detectable in cells expressing caspase-9 DN
(Fig. 3D). This observation is consistent with caspase-9 not
being activated by other caspases but by autocatalysis, as is
expected if caspase-9 is acting as an initiator caspase.
As cells expressing caspase-9 DN manifested no apoptotic
changes after drug treatment, the question arose regarding
whether the signals leading to apoptosis were sent at all. We
reasoned that caspase-9 DN would not affect drug-induced
changes that precede caspase-9 activation because this mutant
is thought to prevent caspase activation by scavenging APAF-1
andyor endogenous caspase-9 (12). Because Cyt c should be
released from mitochondria to participate in caspase-9 acti-
vation (14, 15), we set out to determine whether Cyt c was
released in cells expressing caspase-9 DN.
Staining for Cyt c in untreated IMR90 E1A-caspase-9 DN
cells revealed a characteristic mitochondrial pattern, consis-
tent with the location of this protein in live cells (Fig. 4A). In
contrast, a fraction of treated cells showed a diffuse staining,
indicating that Cyt c was released from mitochondria (16), as
it was in apoptotic IMR90 E1A cells (Fig. 4A). Therefore, the
release of Cyt c was independent of caspase-9 activation and
could precede it. Consistent with this conclusion, the time
course of Cyt c release in cells expressing caspase-9 DN was
similar to the time course of apoptosis in IMR90-E1A cells
(Fig. 4B). Thus, our data indicate that, in cells expressing
caspase-9 DN, etoposide initiated the signals leading to
caspase activation but that the activation did not take place. Of
interest, the treated cells were not viable and died in a few days
without any signs of apoptotic morphology. Whether this death
is caused by the failure to survive with altered mitochondria or
is a caspase-independent part of the apoptotic process remains
to be investigated.
E1A Facilitates Cyt c Release from Mitochondria. Because
our results indicated that caspase-9 is involved in E1A-
dependent apoptosis and because Cyt c is required for
caspase-9 activation, we asked whether E1A sensitizes cells to
drug-induced apoptosis by facilitating Cyt c release. We found
that, although etoposide induced Cyt c release in cells express-
ing E1A irrespective of other manifestations of apoptosis, it
did not have this effect in normal IMR90 cells, except in the
small fraction that underwent apoptosis after etoposide treat-
ment (,5% of the whole population; Fig. 4A and data not
shown). Thus, it appears that E1A controls drug-induced
apoptosis, at least in part, by regulating Cyt c release and
thereby facilitating caspase-9 activation. This facilitation may
be a biochemical mechanism underlying oncogene-induced
sensitization of cells to apoptosis.
It has been suggested that the release of Cyt c can be induced
by caspase-8 activity (17). In addition, effects on Fas-mediated
apoptosis, which proceeds through caspase-8 activation, has
been proposed as the mechanism of oncogene-dependent
sensitization (6). Therefore, we tested whether caspase-8 is
involved in drug-induced cytochrome release in IMR90-E1A
cells. As caspases have to be processed to become active, we
investigated whether processing of caspase-8 is required for
Cyt c release. Caspase-8 was processed in IMR90 E1A cells but
not in the cells expressing caspase-9 DN (Fig. 4C). However,
Cyt c was released in both cell lines, indicating that this release
did not require caspase-8 activity, consistent with evidence
that cells unable to undergo Fas-mediated apoptosis still are
sensitized to apoptosis by oncogenes (5). How E1A regulates
FIG. 3. Oncogene-dependent apoptosis and caspase-9 processing
are blocked in cells by caspase-9 DN. (A) Caspase-9 DN prevents
apoptosis and caspase activation in IMR-90-E1A cells that were
infected with either caspase-9 DN, caspase-9, or vector alone by using
a retroviral gene transfer vector. After 24 hours of treatment with
etoposide (50 mM), apoptotic cells were scored as described in
Materials and Methods. Processing of caspase-3 (B), -7 (C), and -9 (D)
was assessed by immunoblotting. The caspase precursors are indicated
by asterisks, and the processed caspases are indicated by arrows. Note
that the fully processed caspase-3 is not detected because the epitope
for the anti-caspase-3 antibody used (Transduction Laboratories,
Lexington, KY) lies in the prodomain (11).
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the release of Cyt c remains to be elucidated. One way can be
through induction of proteins that release Cyt c such as bax (16,
18). Considering that E1A-dependent bax expression is con-
trolled by p53 (19, 20), one can speculate that the function of
p53 in oncogene-dependent apoptosis is to induce proteins
required for Cyt c release.
Multiple Effects of E1A on the Caspase-9 Activation Com-
plex. Although E1A can control caspase-9 activation by facil-
itating Cyt c release, our findings in vitro suggest that addi-
tional mechanisms are involved. In the cell-free system, trans-
formed and untransformed extracts have similar
concentrations of Cyt c, because breaking mitochondria during
extract preparation bypasses any mechanism that regulates Cyt
c release in cells (7). However, caspases become active only in
transformed extracts, which led us to propose that an activity,
OGA, accounts for the difference. Yet, OGA, which was
identified here as APAF-1, is also present in both extracts, as
is caspase-9.
We noticed that, in cells that express E1A, the levels of
APAF-1 and caspase-9 are increased ('2- and 6-fold, respec-
tively; Fig. 5A), indicating that oncogene expression regulates
not only Cyt c release but also affects other components of the
caspase-9 activating complex. As in cells, the caspase-9 and
APAF-1 levels in transformed extracts were also higher than
those in untransformed extracts (Fig. 5C and data not shown).
To test whether this difference is responsible for oncogene-
dependent caspase activation, we used immunodepletion to
decrease the caspase-9 level in a transformed extract to the
level found in untransformed extracts (Fig. 5 B and C; 10-min
depletion). This depletion decreased the rate of caspase acti-
vation by about half, which could not account for the 75-fold
difference in the rate between transformed and untransformed
extracts. Thus, the increase in the caspase-9 level alone is not
sufficient to explain oncogene-dependent caspase activation,
at least in the cell free system. Whether the effect of oncogenes
FIG. 4. E1A facilitates Cyt c release. (A) After drug treatment, Cyt c is released in transformed but not normal cells. IMR90 (top panels),
IMR90-E1A (middle panels), and IMR90-E1Aycasp9DN (bottom panels) cells were incubated with (‘‘treated’’) or without (‘‘not treated’’) 50 mM
etoposide for 24 hours. The release of Cyt c was visualized by immunofluorescence. White arrows indicate cells with released Cyt c. The chromatin
structure was visualized by staining with 49,6-diamidino-2-phenylindole. The white star indicates a mitotic cell. (B) After etoposide treatment, the
rate of apoptosis in IMR90-E1A cells is similar to the increase in the number of IMR90-E1A-casp9DN cells with released Cyt c. (C) Caspase-8
processing is not required for Cyt c release. Cells were treated as in Fig. 3; caspase-8 processing was assessed by immunoblotting. The two species
of caspase-8 precursor revealed are probably previously reported isoforms (21).
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is limited to quantitative changes of APAF-1 and caspase-9 or
yet-unidentified factors are involved remains to be investi-
gated. In summary, our observations indicate that oncogene
expression sensitizes cells to drug-induced apoptosis by facil-
itating caspase-9 activation. This regulation is likely to be
achieved by several mechanisms, one of which is control of Cyt
c release.
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FIG. 5. E1A expression increases APAF-1 and caspase-9 levels. (A) Levels of APAF-1 and caspase-9 in transformed and untransformed cells
were assessed by immunoblotting by using 25 mg of total cell lysate. (B and C) The difference in caspase-9 levels is not responsible for
oncogene-dependent caspase activation in vitro. Caspase-9 was immunodepleted from a transformed extract to the level present in untransformed
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the extract (B) and the level of caspase-9 (C).
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